Streetbeat News

Analyst Ratings

PACB

Cantor Fitzgerald analyst Ross Osborn has upgraded Pacific Biosciences (NASDAQ:PACB) from Neutral to Overweight and lowered the price target from $14 to $11.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:37 pm

VRDN

RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Viridian Therapeutics (NASDAQ:VRDN), but lowered the price target from $44 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:32 pm

NFLX

A whale investor has taken a bullish stance on Netflix (NASDAQ:NFLX), with 53% of investors opening trades with bullish expectations and 46% with bearish. The whale has been targeting a price range from $5.0 to $420.0 for Netflix over the last 3 months. The price of NFLX is currently down -0.11% at $409.63, and RSI indicators suggest the stock may be approaching overbought.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:31 pm

AMZN

A whale investor has taken a bearish stance on Amazon.com (NASDAQ:AMZN), with 72% of the spotted trades being bearish. The whales have been targeting a price range from $126.0 to $147.5 for Amazon.com over the last 3 months. Several financial firms have maintained or downgraded their ratings on Amazon, with price targets ranging from $160 to $185. The current price of AMZN is $132.81, up 0.08%.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:31 pm

THC

RBC Capital analyst Ben Hendrix has maintained an 'Outperform' rating on Tenet Healthcare (NYSE:THC), but lowered the price target from $87 to $72.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:31 pm

ZI

RBC Capital analyst Rishi Jaluria maintains a 'Sector Perform' rating on ZoomInfo Technologies (NASDAQ:ZI) but has lowered the price target from $22 to $16.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:28 pm

AAPL

META

MSFT

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo discusses trade strategies for SPY, QQQ, AAPL, MSFT, TSLA, and META. The memo provides price levels for these assets based on a proprietary formula that considers price, volume, and options flow. The memo suggests potential bullish and bearish scenarios for each asset and recommends traders to stay alert and adjust their tactics based on the market's pulse.

Portfolio Pulse from RIPS

October 31, 2023 | 2:26 pm

JPM

A significant amount of unusual options activity has been observed for JPMorgan Chase (NYSE:JPM), with a bearish stance being taken by a majority of investors. The price target for JPMorgan Chase over the last 3 months has been between $120.0 and $160.0. The current price of JPM is $138.3, up 0.64%. Several financial institutions have maintained their ratings on JPMorgan Chase, with price targets ranging from $171 to $233.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:17 pm

SRPT

RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Sarepta Therapeutics (NASDAQ:SRPT), but lowered the price target from $217 to $148.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:12 pm

INVZ

Citron Research has praised the CEO of Innoviz Technologies (INVZ) for standing by his team, technology, and customers despite the ongoing war in Israel. The company has over $5 billion in committed contracts. The stock is currently trading below cash value, but Citron Research suggests it could double once the market recognizes Innoviz as the LIDAR leader.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:12 pm